

FACTSHEET

Joint Offering

A First-In-Class Multi-Modal RWD Product That Combines PathAI's Proprietary Tumor Microenvironment Human-Interpretable Features (HIFs) With ConcertAI's EHR-Derived Curated Clinical Datasets



About Our Joint Offering

First-in-class multi-modal RWD product that combines PathAI's proprietary tumor microenvironment human-interpretable features (HIFs) with ConcertAI's EHR-derived curated clinical datasets and pathology whole slide images.

The combined data product offering bridges the patho-physiology of disease from tissue to its clinical manifestation, giving drug developers a powerful research engine for rapid hypothesis generation and testing of novel signals .

Products

RWD360™

Harmonized native structured EMR data with AI insights at a broad population level

200+ variables including:

- Lab results (for diagnosis, stage, response)
- Integrated Line of Therapy (Claims + EMR)
- Diagnosis from EMR
- Real-world overall survival
- Procedures (Transplants, Transfusions, CAR-T)
- ECOG
- Confirmatory curation available

... plus Claims and SDOH data

Patient360™

Expertly abstracted EHR data, via a patient level registry

100+ curated variables including:

- Progression and response (incl. relapse, refractory) directly captured
- Adverse events/toxicities (800+) linked to sentinel events
- Risk Stratification Score
- Longitudinal and genomic information from other labs

...plus all structured, native


PathExplore™

Structured and standardized HIFs that quantify the tumor microenvironment (TME) from digitized H&E-stained biopsies

600+ spatial features including:

- Total Area of Tumor Tissue
- Total Number of Lymphocytes
- Density of Lymphocytes in Cancer Stroma
- Number of Lymphocytes in Proximity to Cancer Cells
- Spatial distribution of Tumor Infiltrating Lymphocytes

...and many more



Exploring TME Biomarkers and Signatures in **Real- World Patient Cohorts** Through Comprehensive Analysis.



Predict impact of histopathology-based biomarkers and signatures in real-world patient cohorts




Identify longitudinal clinical characteristics of biomarker populations



Validate potential TME biomarker signals identified in clinical trial deployments on real-world patient cohorts



Explore the landscape of the TME across large patient populations



Analyze novel prognostic and predictive biomarkers correlated with patient response and outcomes



Assess impact of SDOH on RW outcomes in the context of underlying histological features

Available for: Prostate Cancer, Bladder Cancer, Colorectal Cancer, Melanoma, Lung Cancer, Breast Cancer, Gastric Cancer, Kidney Cancer, Pancreatic Cancer, Lymphoma, Ovarian Cancer, Head & Neck Cancer, and Liver Cancer

Thank You



Contact us **to learn more about**
PathAI and ConcertAI's collaboration

